Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Australian Clinical Labs Ltd ( (AU:ACL) ) has provided an update.
Australian Clinical Labs Limited has provided an update on its on-market share buy-back program for its ordinary fully paid shares traded under the ASX code ACL. The company reported that, as of the latest notification dated 10 March 2026, it had repurchased a cumulative total of 5,482,785 shares prior to the previous day, with an additional 124,363 shares bought back on the previous trading day.
The ongoing buy-back, which was initially notified in October 2025, indicates a continued effort by the company to manage its capital structure and potentially enhance shareholder value. Regular daily updates signal transparency to investors and may reflect management’s view that the current share price undervalues the company’s prospects, although no explicit rationale was detailed in the announcement.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.40 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Limited is an Australian pathology services provider listed on the ASX under the code ACL. The company operates in the medical diagnostics industry, offering laboratory testing and related clinical services across the healthcare sector.
Average Trading Volume: 708,217
Technical Sentiment Signal: Sell
Current Market Cap: A$420.9M
Learn more about ACL stock on TipRanks’ Stock Analysis page.